Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Receivables (2022 - 2025)

Jin Medical International's Receivables history spans 4 years, with the latest figure at $6.1 million for Q3 2025.

  • For Q3 2025, Receivables changed 0.32% year-over-year to $6.1 million; the TTM value through Sep 2025 reached $6.1 million, changed 0.32%, while the annual FY2025 figure was $6.1 million, 0.32% changed from the prior year.
  • Receivables for Q3 2025 was $6.1 million at Jin Medical International, roughly flat from $6.1 million in the prior quarter.
  • Across five years, Receivables topped out at $6.1 million in Q3 2025 and bottomed at $3.4 million in Q3 2023.
  • The 4-year median for Receivables is $5.0 million (2022), against an average of $4.9 million.
  • The largest annual shift saw Receivables decreased 13.24% in 2023 before it skyrocketed 77.26% in 2024.
  • A 4-year view of Receivables shows it stood at $4.0 million in 2022, then fell by 13.24% to $3.4 million in 2023, then surged by 77.26% to $6.1 million in 2024, then grew by 0.32% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Receivables are $6.1 million (Q3 2025), $6.1 million (Q3 2024), and $3.4 million (Q3 2023).